Modality
Nanobody
MOA
IL-13i
Target
Menin
Pathway
Checkpoint
MDS
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
Apr 2020
→ Nov 2030
Phase 1Current
NCT08570753
2,925 pts·MDS
2021-08→2030-11·Active
NCT06198760
2,192 pts·MDS
2020-04→2026-11·Completed
5,117 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-037mo awayPh2 Data· MDS
2030-11-024.6y awayPh2 Data· MDS
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Complet…
P1/2
Active
Catalysts
Ph2 Data
2026-11-03 · 7mo away
MDS
Ph2 Data
2030-11-02 · 4.6y away
MDS
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08570753 | Phase 1/2 | MDS | Active | 2925 | eGFR |
| NCT06198760 | Phase 1/2 | MDS | Completed | 2192 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin |